Ginwa Enterprise (Group) Inc. (SHA:600080)

Market Cap	2.69B -0.9%
Revenue (ttm)	544.04M -7.1%
Net Income	15.58M -79.1%
EPS	0.04 -78.8%
Shares Out	352.71M
PE Ratio	172.40
Forward PE	n/a
Dividend	0.03 (0.37%)
Ex-Dividend Date	n/a

Volume	164,000
Average Volume	10,312,244
Open	7.62
Previous Close	8.02
Day's Range	7.62 - 7.62
52-Week Range	6.71 - 9.35
Beta	0.41
RSI	43.51
Earnings Date	Apr 29, 2026

About Ginwa Enterprise (Group)

Ginwa Enterprise (Group) Inc. researches, develops, produces, markets, and sells traditional Chinese medicines, biological drugs, and chemical drugs primarily in China. The company offers a range of orthopaedics, immunity, children, and general medicines in various dosage forms, including tablets, capsules, granules, powders, mixtures, oral solutions, syrups, and external solutions. It is also involved in the pharmaceutical logistics activities. The company was founded in 1996 and is headquartered in Xi'an, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1996
• Employees: 588
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600080

Financial Performance

In 2025, Ginwa Enterprise (Group)'s revenue was 544.04 million, a decrease of -7.07% compared to the previous year's 585.46 million. Earnings were 15.58 million, a decrease of -79.12%.